Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.

MLA

Leclerc, Jacinthe, et al. “Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.” Circulation. Cardiovascular Quality and Outcomes, vol. 10, no. 10, Oct. 2017. EBSCOhost, https://doi.org/10.1161/CIRCOUTCOMES.117.003891.

APA

Leclerc, J., Blais, C., Rochette, L., Hamel, D., Guénette, L., & Poirier, P. (2017). Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Circulation. Cardiovascular Quality and Outcomes, 10(10). https://doi.org/10.1161/CIRCOUTCOMES.117.003891

Chicago

Leclerc, Jacinthe, Claudia Blais, Louis Rochette, Denis Hamel, Line Guénette, and Paul Poirier. 2017. “Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.” Circulation. Cardiovascular Quality and Outcomes 10 (10). doi:10.1161/CIRCOUTCOMES.117.003891.